PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Add as a preferred source on Google
REDWOOD CITY, Calif., April 02, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being held in Monte Carlo, Monaco.
The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O'Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
